Cancer Protein Biomarker Detection Service

Cancer, as one of the deadly diseases, is a serious threat to human life, so it is extremely critical to diagnose cancer at an early stage. And detection of protein biomarkers can provide a powerful aid for early screening of cancer.

Early detection of protein biomarkers is important for cancer diagnosis. As a professional analyte detection company, CD BioSciences is committed to providing efficient cancer protein biomarker detection service.

Cancer Protein Biomarker Detection by CRIPSR-Cas System

The CRISPR-Cas system is originated from the adaptive immune system of microorganisms such as bacteria, archaea and fungi, and consists of a combination of guide RNA and Cas enzymes. As an emerging technology in the field of biomolecules, it can be used both as a gene editing tool and as a sensitive and efficient biosensing tool. In the field of bioanalysis, the CRISPR-Cas system has the advantage of precise targeting and efficient cleavage of targeted or non-targeted nucleic acids, and thus can be used for protein biomarker detection for cancer diagnosis.

CRISPR-Cas9	CRISPR-Cas13
A new peptide display platform, PICASSO, has been developed using CRISPR-Cas9 technology. Using this platform, DNA molecules can be placed at specific locations on a surface, and each protein in the mixture then self-assembles to the corresponding DNA sequence, and the resulting DNA template protein microarrays allow you to quickly identify antibodies in clinical samples, or to identify any protein of interest to you.	Based on the signal amplification capability of the CRISPR-Cas system, researchers have developed an enzyme-linked immunosorbent assay using CRISPR-Cas13a as a signal amplification strategy, referred to as CLISA. The method allows for the detection of multiple cancer protein biomarkers for disease diagnosis. The CARPID detection uses the CRISPR-Cas13d system to specifically tract a BASU biotin transferase fused to it to the vicinity of lncRNA in living cells, biotinylating the neighboring protein, which is subsequently separated using streptavidin-coupled magnetic beads, followed by label-free quantitative comparative analysis of the separated protein by mass spectrometry to confirm the binding of lncRNA proteins.

CRISPR-Cas9

CRISPR-Cas13

A new peptide display platform, PICASSO, has been developed using CRISPR-Cas9 technology. Using this platform, DNA molecules can be placed at specific locations on a surface, and each protein in the mixture then self-assembles to the corresponding DNA sequence, and the resulting DNA template protein microarrays allow you to quickly identify antibodies in clinical samples, or to identify any protein of interest to you.

Based on the signal amplification capability of the CRISPR-Cas system, researchers have developed an enzyme-linked immunosorbent assay using CRISPR-Cas13a as a signal amplification strategy, referred to as CLISA. The method allows for the detection of multiple cancer protein biomarkers for disease diagnosis.

The CARPID detection uses the CRISPR-Cas13d system to specifically tract a BASU biotin transferase fused to it to the vicinity of lncRNA in living cells, biotinylating the neighboring protein, which is subsequently separated using streptavidin-coupled magnetic beads, followed by label-free quantitative comparative analysis of the separated protein by mass spectrometry to confirm the binding of lncRNA proteins.

Our Services

Utilizing the CRISPR-Cas system's ability to specifically identify and cleave nucleic acid sequences, CD BioSciences offer highly sensitive cancer protein biomarker detection service. In addition, we also provide detection services for nucleic acids, metal ions and small molecules.

Our DeteCas™ platform can detect protein biomarker for different cancer, including but not limited to the followings.

Prostate Cancer

PSA (prostate-specific antigen)
AMACR (alpha-methyl acyl-CoA racemase)
PSMA (prostate-specific membrane antigen)
PAP (prostate acid phosphatase)
FAS (fatty acid synthase)

Liver Cancer

TGF-β1(transforming growth factor beta 1)
AFP (alpha-fetoprotein)
CA19-9 (cancer antigen 19-9)
CEA (carcinoembryonic antigen)

Lung Cancer

CYP-A (cyclophilin A)
MIF (macrophage migration inhibitory factor)
PIGR (polymeric immunoglobulin receptor)
TMS β4 (thymosin beta 4)
CSTA (cysteine protease inhibitor A)
ACBP (acyl-CoA-binding protein)

Breast Cancer

CA15-3 (cancer antigen 15-3)
PCNA (proliferating cell nuclear antigen)
hMAG (human mammaglobin)

Process of Our Service

Advantages of Our Service

High sensitivity for detection of low concentration substances.
High detection efficiency using an optimized CRISPR-Cas system.
Different detection solutions to meet different research needs.
Regular reporting of experimental progress.

CD BioSciences provides affordable, qualified and hassle-free cancer protein biomarker detection service to our global clients. We guarantee on-time delivery of results. We are available to you 24 hours a day, so please feel free to contact us.

Reference

Gong, S.H., et al. CRISPR/Cas-Based In Vitro Diagnostic Platforms for Cancer Biomarker Detection. Analytical Chemistry. 2021, 93(35): 11899-11909.

For research use only. Not intended for any clinical use.